CB2 Insights Inc. (CSE:CBII,Forum) announced on Wednesday that former
Johnson & Johnson executive Peter Cummins has been named as a Director to its Board.
For more on this, click
here.
CB2 was recently selectedby
Drug Science as the exclusive research technology platform for the UK's largest medical cannabis pilot project - TWENTY21. The project aims to enroll 20,000 patients and CB2 will build the patient registry sa well as generate real-world evidence throughout the program.
FULL DISCLOSURE: CB2 Insights Inc. is a client of Stockhouse Publishing.